Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MIP3α-CSP
- Development stage
- Preclinical
- Lead developer
- University of Illinois Chicago
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
MIP3α-CSP is a **fusion protein vaccine construct** comprising the chemokine macrophage inflammatory protein 3 alpha (MIP3α) genetically fused to a **circumsporozoite protein (CSP) antigen** from *Plasmodium falciparum*. The MIP3α component targets the vaccine to immature dendritic cells (iDCs) via C–C motif chemokine receptor 6 (CCR6), promoting robust activation of adaptive immunity. This vaccine is designed to generate protective humoral and cellular immune responses against malaria, demonstrating **enhanced induction of anti-NANP antibody titers** (targeting a key B-cell epitope of CSP) and a greater reduction in liver stage parasite burden in preclinical mouse models compared to CSP-only vaccines. It is under development in mRNA and protein/adjuvant formulations for use as a **malaria vaccine**[1][2][5].
- Other names
- MIP3α-circumsporozoite proteinMIP-3alpha-CSPMIP3alpha-CSPMIP 3alpha-CSPMCSP
02
Targets
CSP (Circumsporozoite protein)CCR6 (C-C motif chemokine receptor 6)
Beyond the preview
Go deeper on MIP3α-CSP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MIP3α-CSP.